SCHEMBL24444145

SCHEMBL24444145

Nc1ncnc2c1ncn2[C@@H]1C[C@H](COP(=O)(O)S)[C@H]1COP(=O)(S)OC[C@H]1O[C@@H](n2cnc3c2ncn2ccnc32)C[C@@H]1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.46
▸ TAS1R3 Q7RTX0 2/20 0.44
▸ TAS1R1 Q7RTX1 2/20 0.44
▸ ENPP1 P22413 3/20 0.44
▸ P2RY1 P47900 2/20 0.44
▸ RNASEL Q05823 1/20 0.42
▸ DNPH1 O43598 1/20 0.42
▸ PRKAB2 O43741 1/20 0.42
▸ TRPM2 O94759 1/20 0.42
▸ LDHA P00338 1/20 0.42
▸ ADRB2 P07550 1/20 0.42
▸ FBP1 P09467 1/20 0.42
▸ SRC P12931 1/20 0.42
▸ ADORA1 P30542 1/20 0.42
▸ P2RY2 P41231 1/20 0.42
▸ PRKAG1 P54619 1/20 0.42
▸ PRKAA2 P54646 1/20 0.42
▸ PDE4D Q08499 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ PRKAA1 Q13131 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258656 0.91 TAS1R3 (0.42) TAS1R3TAS1R1P2RY1RNASELDNPH1
SCHEMBL24258668 0.91 TAS1R3 (0.42) TAS1R3TAS1R1P2RY1RNASELDNPH1
SCHEMBL24258606 0.89 POLB (0.42) POLBTAS1R3TAS1R1ENPP1P2RY1
SCHEMBL24258604 0.85 POLB (0.41) POLBTAS1R3TAS1R1ENPP1P2RY1
SCHEMBL24444137 0.84 POLB (0.42) POLBTAS1R3TAS1R1ENPP1P2RY1
SCHEMBL24258561 0.83 BCHE (0.42) TAS1R3TAS1R1P2RY1RNASELDNPH1
SCHEMBL24258669 0.83 TAS1R3 (0.42) TAS1R3TAS1R1P2RY1RNASELDNPH1
SCHEMBL24258636 0.81 RNASEL (0.42) POLBTAS1R3TAS1R1ENPP1P2RY1
SCHEMBL24680762 0.79 POLB (0.50) POLBTAS1R3TAS1R1ENPP1P2RY1
SCHEMBL8616900 0.78 P2RY1 (0.66) POLBTAS1R3TAS1R1ENPP1P2RY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339185-B2 Cyclic dinucleotides as anticancer agents BRISTOL-MYERS SQUIBB COMPANY (US) 2022-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11339185-B2 Cyclic dinucleotides as anticancer agents DPYD, NTPCR, CD38 POLB 30/4885TAS1R3 4686/4885TAS1R1 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback